Last reviewed · How we verify
NCT05767333
Evaluation of Cicaplast in Subjects With Skin Irritation
trial in Skin Diseases in 109 participants. Completed in 6 June 2022.
6 June 2022
Quick facts
| Lead sponsor | Cosmetique Active International |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 109 |
| Start date | 11 October 2021 |
| Primary completion | 6 June 2022 |
| Estimated completion | 6 June 2022 |
| Sites | 4 locations across China, United States, Poland, Mauritius |
Conditions studied
- Skin Diseases — all drugs for Skin Diseases →
Sponsor
Cosmetique Active International — full company profile →
Who can join
Adults 3 to 70, any sex, with Skin Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this open, before/after, multicentric study is to assess the effect and tolerance of Cicaplast Baume B5 in patients having a skin irritation (irritative and cracked dermatitis, dry eczematids, rubbing irritation, ...) under dermatological control. Patients are asked to apply the product at least twice a day until complete recovery (maximum 21 days).
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05767333
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Skin Diseases
Currently open trials in the same condition.
- NCT07412691 — A Study to Evaluate the Safety of BG-A3004 in Healthy Participants and Patients With Immune-Mediated Skin Diseases · Phase 1 · recruiting
- NCT07091604 — An Observational Study to Assess Objective Skin Pigmentation Variation. · recruiting
- NCT07158879 — Skin Reactions Related to Thoracic Implantable Chamber Dressings · recruiting
- NCT06850311 — Herbal Ointment in Treating Atopic Dermatitis Topically · Phase 2, PHASE3 · recruiting
- NCT06563323 — Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG) · Phase 2 · recruiting
Other Cosmetique Active International trials
Trials by the same sponsor.
- NCT07239726 — CLINICAL INVESTIGATION TO EVALUATE THE EFFICACY AND SAFETY OF EPILADY PROTOTYPE DEVICE FOLLOWED BY APPLICATION OF A TOPI · NA · not yet recruiting
- NCT06590779 — Benefits of a Cosmetic Anti-hair Loss in Males With Hair Loss · NA · not yet recruiting
- NCT06516224 — Anti-pigmenting Effect of a Routine of Facial Products in Subjects With Melasma · NA · not yet recruiting
- NCT07537595 — Efficacy of Cosmetic Products in Preventing Pigmentation Induced by High Energy Visible Light (HEVL) [400-450nm] · completed
- NCT06320314 — Efficacy and Tolerability of Tested Formula After 3 Months in Treatment of Facial Hyperpigmentation of 3 Origins · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05767333 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Cosmetique Active International
- Last refreshed: 14 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05767333.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing